Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel
| Autor: | James G. Herman, Malcolm V. Brock, Dongtao Yin, Dan Gao, Mingzhou Guo, Yang Liu, Tianyang Yun, Enqiang Linghu, Qimin Zhan |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
5-aza-2′-deoxycytidine
Oncology Cancer Research medicine.medical_specialty CHFR esophageal squamous cell cancer Cell cycle phase paclitaxel chemistry.chemical_compound Internal medicine Genetics medicine docetaxel DNA methylation Taxane business.industry Cell cycle medicine.disease Docetaxel Paclitaxel chemistry Dysplasia chemo-sensitivity business Research Paper medicine.drug |
| Zdroj: | Genes & Cancer |
| ISSN: | 1947-6027 |
| DOI: | 10.18632/genesandcancer.46 |
| Popis: | Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies worldwide. Both genetic and epigenetic changes are involved in esophageal carcinogenesis. CHFR methylation has been found frequently in different cancers and is regarded as a marker of taxane sensitivity. CHFR methylation was found in 0% (0/16) of normal mucosa, 2.9% (1/34) of grade I dysplasia, 0% (0/8) of grade II dysplasia, 12.5% (1/8) of grade III dysplasia and 45% (49/109) of invasive cancer. When treated with docetaxel or paclitaxel, cell viability was lower in CHFR methylated esophageal cancer cells than in unmethylated cells (p0.05). In CHFR methylated cells, treatment with docetaxel or paclitaxel resulted in almost all cells being suspended in G0/G1 phase of the cell cycle. After 5-AZ treatment, there was an increased fraction of CHFR-methylated cells in S and G2/M phases (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|